Mostrar el registro sencillo del ítem
Calcipotriol/Betamethasone Dipropionate Aerosol Foam for Plaque Psoriasis: A Prospective, Observational, Non-Interventional, Single-Center Study of Patient Adherence and Satisfaction in Daily Use
dc.contributor.author | Navarro Triviño, Francisco José | |
dc.contributor.author | Lozano Lozano, Mario | |
dc.contributor.author | Ruiz Villaverde, Ricardo | |
dc.date.accessioned | 2021-09-17T06:36:27Z | |
dc.date.available | 2021-09-17T06:36:27Z | |
dc.date.issued | 2021-05-20 | |
dc.identifier.citation | Navarro-Triviño FJ, Lozano-Lozano M, Ruiz-Villaverde R. Calcipotriol/betamethasone aerosol foam for plaque psoriasis: a prospective, observational, non-interventional, single-center study on patient adherence and satisfaction in daily use. Dermatol Pract Concept. 2021;11(3):e2021056. DOI: [https://doi.org/10.5826/dpc.1103a56] | es_ES |
dc.identifier.uri | http://hdl.handle.net/10481/70244 | |
dc.description | This research was funded by Leo Pharma. | es_ES |
dc.description.abstract | Background: Psoriasis is a chronic inflammatory disease that has a negative impact on patients’ quality of life. Patients with mild–moderate psoriasis can be treated with topical medications, such as the combination drug calcipotriol/betamethasone dipropionate (Cal/BD). Objectives: This study investigated the adherence of psoriasis patients to therapy with Cal/BD aerosol foam, as well as their satisfaction with the treatment’s efficacy, safety, and effect on their quality of life. Methods: Patients with mild–moderate plaque psoriasis were eligible to participate in this open-label, non-placebo controlled, prospective single-center study. Adherence to treatment was assessed using the Morisky-Green scale 4 and 12 weeks after the start of treatment. Satisfaction with the treatment was assessed using the abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9). The severity of psoriasis was assessed on the mIGA and PGA scales, and the impact on quality of life was assessed using the PDI and DLQI scales. Results: A total of 65 patients entered the study. Adherence to treatment was good, with 73.8% of patients showing high adherence at 12 weeks. Satisfaction was also good, with 46 patients (70.8%) being completely satisfied. Conclusions: Over a 4-week period, patients treated with Cal/BD aerosol foam had significant improvement in disease severity that was directly related to treatment adherence. | es_ES |
dc.description.sponsorship | LEO Pharma | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Derm101 | es_ES |
dc.rights | Atribución-NoComercial 3.0 España | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/3.0/es/ | * |
dc.subject | Adherence | es_ES |
dc.subject | Satisfaction | es_ES |
dc.subject | Calcipotriol/betamethasone | es_ES |
dc.subject | Aerosol foam | es_ES |
dc.subject | Psoriasis | es_ES |
dc.title | Calcipotriol/Betamethasone Dipropionate Aerosol Foam for Plaque Psoriasis: A Prospective, Observational, Non-Interventional, Single-Center Study of Patient Adherence and Satisfaction in Daily Use | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es_ES |
dc.identifier.doi | 10.5826/dpc.1103a56 | |
dc.type.hasVersion | info:eu-repo/semantics/publishedVersion | es_ES |